Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Study 1: The SURMOUNT-1 Trial (Obesity) Title: TZ Once Weekly for the Treatment of Obesity Summary: This landmark Phase 3 trial demonstrated that Tirzepatide achieved substantial reductions in body weight (up to 20.9%) in non-diabetic subjects, significantly outperforming placebo
Yes, semaglutide is more effective for weight loss than liraglutide because semaglutide has a greater half-life than liraglutide
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Orlistat blocks some of the fat that you eat, keeping it from being absorbed by your body
